Kei Yamane

Dr. Kei Yamane


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2023 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
KYKei Yamane
Kei Yamane
TATakayuki Anazawa
Takayuki Anazawa
KNKazuyuki Nagai
Kazuyuki Nagai
TITakashi Ito
Takashi Ito
EHEtsuro Hatano
Etsuro Hatano
Total pancreatectomy with islet autotransplantation (TPIAT) is an established and effective treatment modality for patients diagnosed with intractable chronic pancreatitis (CP) and recurrent acute pancreatitis (RAP). TPIAT primarily aims to manage debilitating pain leading to impaired quality of life among patients with CP or RAP, which can be successfully managed with medical, endoscopic, or surgical interventions. TPIAT is significantly successful in relieving pain associated with CP and improving health‐related quality of life outcomes. Furthermore, the complete loss of pancreatic endocrine function attributed to total pancreatectomy (TP) can be compensated by autologous islet transplantation (IAT). Patients receiving IAT can achieve insulin independence or can be less dependent on exogenous insulin compared with those receiving TP alone. Historically, TPIAT has been mainly used in the United States, and its outcomes have been improving due to technological advancements. Despite some challenges, TPIAT can be a promising treatment for patients with CP‐related intractable pain. Thus far, TPIAT is not commonly performed in Japan. Nevertheless, it may improve health‐related quality of life in Japanese patients with CP, similar to Western patients. This review article aimed to provide an overview of the indications, related procedures, and outcomes of TPIAT and to discuss future prospects in Japan.

21 April 2025 in Pancreatology
Verified
Journal Article
Open access
KYKei Yamane
Kei Yamane
KMKoshiro Morino
Koshiro Morino
TATakayuki Anazawa
Takayuki Anazawa
KNKazuyuki Nagai
Kazuyuki Nagai
ASAsahi Sato
Asahi Sato
EHEtsuro Hatano
Etsuro Hatano
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis with high recurrence rates following curative resection. Locoregional treatment (LT), including metastasectomy, radiation therapy, and radiofrequency ablation, has shown potential survival benefits in selected patients with recurrent PDAC. However, criteria for selecting patients who may benefit from LT remain unclear. The aim of this study is to define oligo-recurrence in PDAC by evaluating the impact of LT on survival after recurrence (SAR). Among 586 patients who underwent curative pancreatectomy between 2006 and 2022, 380 developed recurrence and were included in this study. The primary outcome was SAR, with prognostic factors identified using multivariate Cox regression analysis. Subgroup analysis was performed to identify the patient profiles most likely to benefit from LT. LT was performed in 79 patients (20.8 %) and not in 301 patients (79.2 %). Independent predictors of poor SAR included time to recurrence (TTR) ≤ 12 months, CA19-9 > 200 U/mL at recurrence, and multi-organ recurrence or ≥ 4 tumors (P < 0.001 for each). Subgroup analysis of these factors identified two groups with significant survival benefits from LT: patients with "TTR >12 months" and "single-organ recurrence (SOR) with ≤3 tumors," with or without "CA19-9 > 200 U/mL." Patients with recurrent PDAC characterized by "TTR >12 months" and "SOR with ≤3 tumors" may achieve long-term survival with LT, leading to the proposal of defining them as having "oligo-recurrence" in PDAC.

15 May 2023 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
KYKei Yamane
Kei Yamane
YUYosuke Umino
Yosuke Umino
TNTadashi Nagami
Tadashi Nagami
KTKoji Tarumoto
Koji Tarumoto
KHKuniaki Hattori
Kuniaki Hattori
AKAkiyoshi Kanazawa
Akiyoshi Kanazawa

21 July 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KYKei Yamane
Kei Yamane
TATakayuki Anazawa
Takayuki Anazawa
STSeiichiro Tada
Seiichiro Tada
NFNanae Fujimoto
Nanae Fujimoto
KIKenta Inoguchi
Kenta Inoguchi
SUShinji Uemoto
Shinji Uemoto
The in vitro culture period prior to cell transplantation (i.e. pancreatic islet transplantation) enables cell modification and is thus advantageous. However, the islet preconditioning method has not been fully explored. Here we present a simple approach for islet preconditioning that uses the antibiotic mitomycin C (MMC), which has antitumor activity, to reduce islet immunogenicity and prevent proinflammatory events in an intraportal islet transplantation model. Freshly isolated mice islets were treated for 30 min with 10 μg/mL MMC or not, cultured for 20 h and transplanted into the livers of syngeneic or allogeneic diabetic mouse recipients. In the allogeneic model, MMC preconditioning significantly prolonged graft survival without requiring immunosuppressants. In vitro, MMC treatment suppressed the expression of proinflammatory cytokines in islet allografts, while immunohistochemical studies revealed the suppression of inflammatory cell infiltration into MMC-treated allografts relative to untreated allografts. Furthermore, MMC preconditioning significantly suppressed the mRNA expression of proinflammatory cytokines into the transplant site and induced the differentiation of regulatory T cells with the ability to suppress CD4+ T cell-mediated immune responses. In conclusion, islet preconditioning with MMC prolonged graft survival in an intraportal islet transplantation model by suppressing proinflammatory events and inducing potentially regulatory lymphocytes.

17 March 2026 in Annals of Surgery
Verified
Journal Article
Open access
KYKei Yamane
Kei Yamane
KNKazuyuki Nagai
Kazuyuki Nagai
TATakayuki Anazawa
Takayuki Anazawa
YKYosuke Kasai
Yosuke Kasai
ASAsahi Sato
Asahi Sato
EHEtsuro Hatano
Etsuro Hatano
Objective: We evaluated the prognostic significance and implications of a major pathologic response (MPR) after preoperative treatment for pancreatic ductal adenocarcinoma (PDAC). Summary Background Data: Preoperative treatment is increasingly used for PDAC to improve oncologic outcomes. The pathologic response represents a potential indicator of treatment efficacy; however, its prognostic value in PDAC remains unclear. Methods: We retrospectively analyzed 739 patients who underwent pancreatectomy for PDAC after preoperative treatment at 21 institutions in Japan. The pathologic response was graded using Evans’ classification, with MPR defined as Evans grade III/IV. Survival outcomes and prognostic factors were evaluated, and factors associated with achieving MPR were analyzed to develop a predictive model. Results: MPR was achieved in 11.5% of patients. The MPR group had a significantly longer median overall survival (71.5 vs. 40.9 mo) and recurrence-free survival (55.5 vs. 15.2 mo) than the non-MPR group. Multivariate analysis identified MPR as an independent prognostic factor for overall survival. In the MPR subgroup, neither overall nor recurrence-free survival differed according to adjuvant chemotherapy administration; multivariate analysis did not identify adjuvant therapy as an independent prognostic factor. Predictive factors for achieving MPR included chemoradiotherapy, preoperative duration ≥6 months, normal carbohydrate antigen 19-9 after preoperative treatment, and complete or partial radiologic response. Finally, we developed a simplified predictive model for achieving MPR. Conclusions: MPR was independently associated with favorable survival in PDAC. The prognostic impact of adjuvant chemotherapy was not observed among patients who achieved MPR, suggesting that MPR may inform individualized postoperative management and warrants prospective validation.